Paggiosi, M. A.
Yang, L.
Blackwell, D.
Walsh, J. S.
McCloskey, E.
Peel, N.
Eastell, R.
Article History
Received: 9 April 2017
Accepted: 12 February 2018
First Online: 8 March 2018
Compliance with ethical standards
:
: MAP, LY, and DB state no disclosure. JSW has received speaker’s honoraria from Lilly, grant funding from Alexion and Immunodiagnostic Systems, donation of drug from Prostrakan for a clinical trial, consulting fees from Shire and Mereo Biopharma. NP has received speaker’s honoraria and participated in advisory board activities for Eli Lilly and Prostraken. EVM has received consultancy payments from Merck, UCB, Consilient, speaker fees from Bayer, Consilient, GSK, Amgen, UCB, Roche, Servier, Lilly, and payment for development from Lilly. RE has received consultancy payments, speaker fees, and grant funding from Eli Lilly and Company. Teriparatide was provided by Eli Lilly and Company, Basingstoke, UK to the University of Sheffield through an Investigator-Initiated Trial (IIT) award. The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health (DoH).